Anna Tagliabue1, Cinzia Ferraris2, Francesca Uggeri3, Claudia Trentani2, Simona Bertoli4, Valentina de Giorgis5, Pierangelo Veggiotti5, Marina Elli3. 1. Human Nutrition and Eating Disorder Research Center, Department of Public Health, Experimental and Forensic Medicine University of Pavia, Pavia, Italy. Electronic address: anna.tagliabue@unipv.it. 2. Human Nutrition and Eating Disorder Research Center, Department of Public Health, Experimental and Forensic Medicine University of Pavia, Pavia, Italy. 3. AAT-Advanced Analytical Technologies Srl, Piacenza, Italy. 4. International Center for the Assessment of Nutritional Status (ICANS), Department of Food Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy. 5. Department of Child Neurology and Psychiatry, C. Mondino National Neurological Institute, Via Mondino, 2, 27100, Pavia, Italy.
Abstract
BACKGROUND&AIMS: The classical ketogenic diet (KD) is a high-fat, very low-carbohydrate normocaloric diet used for drug-resistant epilepsy and Glucose Transporter 1 Deficiency Syndrome (GLUT1 DS). In animal models, high fat diet induces large alterations in microbiota producing deleterious effects on gut health. We carried out a pilot study on patients treated with KD comparing their microbiota composition before and after three months on the diet. METHODS: Six patients affected by GLUT1 DS were asked to collect fecal samples before and after three months on the diet. RT - PCR analysis was performed in order to quantify Firmicutes, Bacteroidetes, Bifidobacterium spp., Lactobacillus spp., Clostridium perfringens, Enterobacteriaceae, Clostridium cluster XIV, Desulfovibrio spp. and Faecalibacterium prausnitzii. RESULTS: Compared with baseline, there were no statistically significant differences at 3 months in Firmicutes and Bacteroidetes. However fecal microbial profiles revealed a statistically significant increase in Desulfovibrio spp. (p = 0.025), a bacterial group supposed to be involved in the exacerbation of the inflammatory condition of the gut mucosa associated to the consumption of fats of animal origin. CONCLUSIONS: A future prospective study on the changes in gut microbiota of all children with epilepsy started on a KD is warranted. In patients with dysbiosis demonstrated by fecal samples, it my be reasonable to consider an empiric trial of pre or probiotics to potentially restore the «ecological balance» of intestinal microbiota.
BACKGROUND&AIMS: The classical ketogenic diet (KD) is a high-fat, very low-carbohydrate normocaloric diet used for drug-resistant epilepsy and Glucose Transporter 1 Deficiency Syndrome (GLUT1 DS). In animal models, high fat diet induces large alterations in microbiota producing deleterious effects on gut health. We carried out a pilot study on patients treated with KD comparing their microbiota composition before and after three months on the diet. METHODS: Six patients affected by GLUT1 DS were asked to collect fecal samples before and after three months on the diet. RT - PCR analysis was performed in order to quantify Firmicutes, Bacteroidetes, Bifidobacterium spp., Lactobacillus spp., Clostridium perfringens, Enterobacteriaceae, Clostridium cluster XIV, Desulfovibrio spp. and Faecalibacterium prausnitzii. RESULTS: Compared with baseline, there were no statistically significant differences at 3 months in Firmicutes and Bacteroidetes. However fecal microbial profiles revealed a statistically significant increase in Desulfovibrio spp. (p = 0.025), a bacterial group supposed to be involved in the exacerbation of the inflammatory condition of the gut mucosa associated to the consumption of fats of animal origin. CONCLUSIONS: A future prospective study on the changes in gut microbiota of all children with epilepsy started on a KD is warranted. In patients with dysbiosis demonstrated by fecal samples, it my be reasonable to consider an empiric trial of pre or probiotics to potentially restore the «ecological balance» of intestinal microbiota.
Authors: Maria Eduarda T Oliveira; Gustavo V B Paulino; Erivaldo D Dos Santos Júnior; Francisca A da Silva Oliveira; Vânia M M Melo; Jeferson S Ursulino; Thiago M de Aquino; Ashok K Shetty; Melissa Fontes Landell; Daniel Leite Góes Gitaí Journal: Mol Neurobiol Date: 2022-08-13 Impact factor: 5.682
Authors: David Ma; Amy C Wang; Ishita Parikh; Stefan J Green; Jared D Hoffman; George Chlipala; M Paul Murphy; Brent S Sokola; Björn Bauer; Anika M S Hartz; Ai-Ling Lin Journal: Sci Rep Date: 2018-04-27 Impact factor: 4.379
Authors: John Michael S Sanchez; Ana Beatriz DePaula-Silva; Jane E Libbey; Robert S Fujinami Journal: Clin Immunol Date: 2020-03-07 Impact factor: 3.969